JPMorgan Chase & Co. Issues Pessimistic Forecast for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective lowered by JPMorgan Chase & Co. from $12.00 to $10.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 5.71% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Mizuho dropped their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, October 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Friday, October 30th. BMO Capital Markets lowered their price target on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating on the stock in a research report on Thursday, September 17th. Barrington Research lowered their price target on DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating on the stock in a research report on Monday, October 26th. Finally, Barclays raised their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $12.42.

DENTSPLY SIRONA Price Performance

XRAY stock opened at $9.46 on Friday. The firm has a market cap of $1.89 billion, a PE ratio of -15.26, a P/E/G ratio of 1.27 and a beta of 0.87. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.04 and a current ratio of 1.63. The firm’s fifty day moving average is $9.60 and its 200 day moving average is $11.28. DENTSPLY SIRONA has a one year low of $8.14 and a one year high of $14.76.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.02). The firm had revenue of $836.00 million during the quarter, compared to analyst estimates of $861.68 million. DENTSPLY SIRONA had a positive return on equity of 20.21% and a negative net margin of 3.38%. The company’s revenue was down 7.5% on a year-over-year basis. During the same quarter last year, the company posted $0.37 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. On average, research analysts forecast that DENTSPLY SIRONA will post 1.33 EPS for the current year.

Institutional Trading of DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently modified their holdings of XRAY. BlackRock Inc. acquired a new stake in shares of DENTSPLY SIRONA in the second quarter worth approximately $283,405,000. Southpoint Capital Advisors LP acquired a new position in DENTSPLY SIRONA in the 1st quarter valued at $116,000,000. Edmond DE Rothschild Holding S.A. acquired a new position in DENTSPLY SIRONA in the 2nd quarter valued at $47,780,000. Paradigm Capital Management Inc. NY purchased a new position in DENTSPLY SIRONA in the 2nd quarter valued at $39,775,000. Finally, Dimensional Fund Advisors LP lifted its holdings in DENTSPLY SIRONA by 31.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,559,388 shares of the medical instruments supplier’s stock valued at $41,284,000 after purchasing an additional 850,261 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.